Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2016
Cancer drugs - the case for Keytruda
3 March 2016 - Is Pharmac’s decision not to prioritise funding melanoma drug Keytruda a case of “putting money before people”, ...
Posted by Michael Wonder on 03 Mar 2016
Great voice heard
3 March 2016 - The NZ Government has all but promised that a melanoma drug will be funded by Pharmac after ...
Posted by Michael Wonder on 02 Mar 2016
Tough choices in melanoma drug debate
2 March 2016 - Consider this, you're a multinational company peddling a relatively new melanoma cancer drug that's been effective for ...
Posted by Michael Wonder on 01 Mar 2016
New Zealand Pharmaceutical Schedule - 1 March 2016 update
1 March 2016 - the March 2016 issue of the Schedule sees the listing of a number of new medicines/combination ...
Posted by Michael Wonder on 29 Feb 2016
Tauranga woman fights for life-saving drug
1 March 2016 - Patients such as Tauranga's Leisa Renwick, who have had miraculous results with melanoma drugs, will join dying ...
Posted by Michael Wonder on 28 Feb 2016
Miracle' med too costly for patient
27 February 2016 - Tourette Syndrome sufferer distraught over inability to continue paying for life-changing Sativex prescription. ...
Posted by Michael Wonder on 26 Feb 2016
Medicines NZ calls for Government funding of melanoma wonder drug
26 February 2016 - Medicines NZ, a pharmaceutical company lobby group, say that the Pharmac model is broken and needs to ...
Posted by Michael Wonder on 17 Feb 2016
Kaitaia woman's medical win
16 February 2016 - A Kaitaia woman is the first person in New Zealand to receive publicly-funded medical cannabis to control ...
Posted by Michael Wonder on 12 Feb 2016
Approval of amendments to the listing of some respiratory products
12 February 2016 - PHARMAC is pleased to announce the approval of amendments to existing listing agreements with Novartis New Zealand ...
Posted by Michael Wonder on 11 Feb 2016
Summary of responses to PHARMAC’s consultation on improving access to medicines and devices in primary care
9 February 2016 - PHARMAC received feedback from a range of stakeholders including suppliers, wholesalers, general practice and their professional bodies ...
Posted by Michael Wonder on 09 Feb 2016
More treatments funded by PHARMAC for respiratory disease
9 February 2016 - PHARMAC is funding six new medicines that will improve treatment options for people with chronic obstructive pulmonary ...
Posted by Michael Wonder on 05 Feb 2016
PHARMAC decision relating to filgrastim and methotrexate pre-filled syringes
5 February 2016 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd. involving filgrastim, ...
Posted by Michael Wonder on 03 Feb 2016
PHARMAC decision relating to a number of respiratory products
3 February 2016 - PHARMAC is pleased to announce the approval of agreements with Boehringer Ingleheim and GlaxoSmithKline involving a number ...
Posted by Michael Wonder on 01 Feb 2016
Dad pushing for a subsidy on EpiPens
30 January 2016 - A Whanganui father wants EpiPens to be funded by PHARMAC. ...
Posted by Michael Wonder on 31 Jan 2016
New Zealand Pharmaceutical Schedule - 1 February 2016 update
1 February 2016 - The second issue of the Schedule for 2016 sees the listing of two new medicines: dimethyl ...